Watkins Tim 4
4 · Contineum Therapeutics, Inc. · Filed Apr 28, 2025
Insider Transaction Report
Form 4
Watkins Tim
CMO & Head of Development
Transactions
- Award
Stock Option (right to buy)
2025-04-28+26,000→ 26,000 totalExercise: $4.50Exp: 2035-04-27→ Class A Common Stock (26,000 underlying) - Award
Stock Option (right to buy)
2025-04-28+260,000→ 260,000 totalExercise: $4.50Exp: 2035-04-27→ Class A Common Stock (260,000 underlying)
Footnotes (2)
- [F1]Options granted outside of the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). One-half of the option shares vest on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.
- [F2]Options granted outside of the Plan, pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). This grant is subject to a performance-based vesting condition to be satisfied upon the achievement of a particular clinical milestone, based on such performance condition being satisfied within two years of the grant date and subject to the Reporting Person's continuous service.